ClinicalTrials.gg
RecruitingNCT05952375Updated Jul 19, 2023

Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial

An interventional study of Chimeric antigen receptor T cell preparation targeting Claudin18.2 in Gastric Cancer, sponsored by The Affiliated Hospital of Qingdao University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-19.

Sponsored by The Affiliated Hospital of Qingdao University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Mar 2023, registered Jul 2023).
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University — 12 open to participants now, 14 under way, 1 of them phase 3. Stomach Neoplasms · The Affiliated Hospital of Qingdao University.

Planned enrollment
13th of 13
9 · median 300
Started
2023
with 3 others
No phase
12 of 16
9 open now
Primary completion
2025-02
later than 6 of 13 live
Registered
4th of 16
by date

Among the 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University, this one is the 13th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2023, is one of 12 with no phase, reaches primary completion later than 6 of the 13 other live ones, and was the 4th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

12 of the 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assessing the safety and tolerability of XKDCT086 cells against recurrent or refractory solid tumors with Claudin18.2 positivity.This experiment proposes to enroll 9-18 patients, the experimental drug is a chimeric antigen receptor T cell preparation targeting Claudin18.2.

Read the detailed description

This study adopts a single arm, single center, and dose increasing design, using a "3+3" design for dose increasing to evaluate the safety, tolerance, and effectiveness of XKDCT086 cells, as well as to evaluate the pharmacokinetic characteristics of XKDCT086 cells, the correlation between cytokines and efficacy, and immunogenicity.

The experimental process of this study is divided into seven stages: screening period, blood collection period, baseline period, clearance period, study treatment and safety observation period after treatment, follow-up period, and long-term follow-up.

03

Conditions studied

  • Gastric Cancer

Browse trials for

Keywords

  • Chimeric Antigen
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Age range from 18 to 75 years old (including threshold), regardless of gender;

      1. Patients with advanced solid malignant tumors with positive expression of Claudin 18.2 (including but not limited to gastric cancer, esophageal gastric junction adenocarcinoma, and esophageal adenocarcinoma); And after sufficient treatment, the condition cannot be completely relieved or continue to progress;;
      1. At least one (non lymph node lesion with a length diameter of ≥ 10mm and lymph node lesion with a short diameter of ≥ 15mm) using the 1.1 standard;
      1. Expected survival time ≥ 12 weeks;
      1. score 0-1 points;
      1. The laboratory test values conducted for screening must meet the following standards:

Blood routine examination:

WBC ≥ 3.0 × 10\^9/L

≥ 1.5 × 10\^9/L

HB ≥ 80g/L (no blood transfusion received within 2 weeks)

≥ 100 × 10\^9/L

Blood biochemical examination:

and AST ≤ 2.5 × (≤ 5 if accompanied by liver ) × ULN

ALB ≥ 30g/L

Serum creatinine ≤ 1.5 × ULN or >50mL/min (GFR=[(140 age) × weight × (0.85 female)]/(72 × Scr)

≤ 1.5 × ULN

Coagulation function test:

≤ 1.5ULN, while INR or PT ≤ 1.5ULN (without receiving anticoagulant therapy)

  1. Women of childbearing age must undergo serum pregnancy tests during screening and before receiving clearance treatment, and the results must be negative;
  1. If the patient uses the following drugs, the corresponding situation must be met:

: Treatment doses of steroids must be discontinued 4 weeks before XKDCT086 infusion. However, physiological alternative doses of steroids are allowed: hydrocortisone or equivalent\<6-12mg/mm2/day;

: Any immunosuppressive drug must be stopped at least 4 weeks before enrollment;

  1. Voluntarily participate in clinical trials and sign an form.

Exclusion criteria

Exclusion Criteria:

    1. Pregnant or lactating women;

      1. Active , or other infectious diseases (syphilis, )
      1. Any active infection that requires antibiotic treatment;
      1. Have received any immune cell therapy within one year;
      1. Those who had received /PD-L1 Targeted therapy in the past and had serious adverse reactions (the investigator judged whether they were suitable for inclusion);
      1. Have received Targeted therapy drugs of Claudin18.2 in the past;
      1. Inoculate with or attenuated live vaccines within 4 weeks before single collection;
      1. Allergic or intolerant to the research drug Tocilizumab, fludarabine, Cyclophosphamide and other anti drenching drugs selected by the researcher;
      1. Uncontrolled cardio cerebral Vascular disease, such as heart failure or others, existed within 6 months before enrollment;
      1. Within the 6 months prior to enrollment in the study, the subjects had a history of arrhythmia or were currently in need of treatment β Abnormalities of antiarrhythmic therapy other than receptor blockers or Digoxin and/or conduction drugs, except atrial fibrillation and paroxysmal supraventricular tachycardia;
      1. (LVEF)\<50% at screening;
      1. Patients with active diseases, such as systemic lupus erythematosus, within the first 3 months of screening; Those who require continuous medication throughout the entire trial period;
      1. Before single collection, oxygen inhalation is required to maintain a fingertip blood oxygen saturation of ≥ 95%;
      1. Other malignant tumors occurred within 5 years before enrollment, except for cervical Carcinoma in situ, Cutaneous squamous-cell carcinoma or Basal-cell carcinoma which had been treated for radical treatment before;
      1. Suffering from known symptomatic central nervous system (CNS) diseases;
      1. Surgery was performed within 2 weeks prior to single collection and the researchers believe it may affect patient safety;
      1. The maximum target lesion is greater than 40mm;
      1. The widespread of tumors involving more than two organs may significantly alter the baseline assessment, the researchers believe; Or the tumor progression is rapid, and from enrollment to clearance, the tumor has reached PD;
      1. Those whose hydrothorax and ascites are greater than grade 2 and cannot be controlled by discharge or Diuretic;
      1. Tumor cells infiltrate the central nervous system, and tumor cells are detected in cerebrospinal fluid or detected on cranial imaging;
      1. The subject has unstable or active gastric ulcers or active gastrointestinal bleeding, or other situations that may require emergency treatment during the trial period, including but not limited to gastrointestinal obstruction, perforation, and massive tumor rupture;
      1. The subject has been taking Anticoagulant all the time and cannot stop taking the drug during the whole test process.
      1. Uncontrollable diabetes (>8%), uncontrolled hypertension (systolic blood pressure/diastolic blood pressure>160mmHg/100mmHg under medication);
      1. Difficult airways (tumor growth obstructs airways or airway deformities, etc.);
      1. People who are allergic to commonly used first aid and Narcotic;

According to the judgment of the researcher, patients who are not suitable to participate in this study.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    XKDCT086 treatment for patients with Claudin18.2 target positivity

    Drug: XKDCT086 (chimeric antigen receptor T cell preparation targeting Claudin18.2) Dosage form: Cell suspension Dose: 30-50mL/bag Medication method: intravenous drip Frequency: Once

    Drug: Chimeric antigen receptor T cell preparation targeting Claudin18.2

Interventions

  • DrugChimeric antigen receptor T cell preparation targeting Claudin18.2

    Chimeric antigen receptor T cell preparation targeting Claudin18.2

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE)

    o characterize the safety profile of XKDCT086 in patients with advanced solid tumor

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Feb 2025, 23 months after the start.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 23 months is below that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Jul 19, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Feb 28, 2025
CompletionEst.
Feb 28, 2025
Last update
Jul 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05952375
Responsible party
Sponsor
First posted
Jul 19, 2023
Start date
Mar 1, 2023
Primary completion
Feb 28, 2025 (estimated)
Completion
Feb 28, 2025 (estimated)
Last update
Jul 19, 2023

Study contacts

YU cao, MD
Contact
caoyu1767@126.com
18661809090
YU cao
Contact
caoyu1767@126.com
18661809090
YU cao, MD
principal investigator · The Affiliated Hospital of Qingdao University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion